论文部分内容阅读
目的 探讨多药耐药基因 (MDR1)在子宫颈癌组织中的表达及其临床意义。方法 利用逆转录聚合酶链反应 (RT -PCR)方法检测 46例子宫颈癌组织MDR1基因表达情况 ,同时利用四甲基偶氮唑篮比色法(MTT)检测肿瘤细胞对化疗药的敏感性。结果 2 8例 (6 1% )宫颈癌组织MDR1基因表达阳性 ,MDR1基因表达与肿瘤细胞组织学分级有关 (P <0 0 5 ) ,而与肿瘤组织学类型及临床分期无关。MDR1表达阳性的宫颈癌细胞对长春新碱、阿霉素和足叶乙甙交叉耐药。结论 MDR1基因表达阳性的子宫颈癌可能对长春新碱、阿霉素和足叶乙甙耐药 ,顺铂可作为子宫颈癌化疗的首选药物。MDR1基因的表达可能与宫颈癌的预后有关
Objective To investigate the expression of multidrug resistance gene (MDR1) in cervical cancer and its clinical significance. Methods Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the expression of MDR1 gene in 46 cases of cervical cancer. Simultaneously, the sensitivity of tumor cells to chemotherapeutic drugs was detected by MTT assay. Results MDR1 gene expression was positive in 28 cases (6 1%) of cervical cancer tissues. The expression of MDR1 gene was related to the histological grade of tumor cells (P < 0.05), but it was not related to histological type and clinical stage. MDR1-positive cervical cancer cells were cross-resistant to vincristine, doxorubicin, and etoposide. Conclusion MDR1 positive cervical cancer may be resistant to vincristine, doxorubicin and etoposide, and cisplatin may be the first choice for chemotherapy for cervical cancer. MDR1 gene expression may be related to the prognosis of cervical cancer